High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron

Ulrike Baum[1*], Eero Poukka[1,2*†], Tuija Leino[1], Terhi Kilpi[3], Hanna Nohynek[1], Arto A. Palmu[4]

1. Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
2. University of Helsinki, Faculty of Medicine, Helsinki, Finland
3. Management, Research, Development and Innovation, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
4. Population Health Unit, Department of Public Health and Welfare, Finnish Institute for Health and Welfare (THL), Tampere, Finland

* Contributed equally to this work

† Corresponding author: Eero Poukka (+358 29 524 7956, eero.poukka@thl.fi);

Finnish Institute for Health and Welfare, Mannerheimintie 166, 00300 Helsinki, Finland

Abstract

Background.

The elderly are highly vulnerable to severe Covid-19. Waning immunity and emergence of Omicron have

caused concerns about reduced effectiveness of Covid-19 vaccines. The objective was to estimate vaccine

effectiveness (VE) against severe Covid-19 among the elderly.

Methods.

This nationwide, register-based cohort analysis included all residents aged 70 years and over in Finland. The

follow-up started on December 27, 2020, and ended on March 31, 2022. The outcomes of interest were

Covid-19-related hospitalization and intensive care unit (ICU) admission timely associated with SARS-CoV-2

infection. VE was estimated as one minus the hazard ratio comparing the vaccinated and unvaccinated and

taking into account time since vaccination. Omicron-specific VE was evaluated as the effectiveness

observed since January 1, 2022.

Results.

The cohort included 896220 individuals. Comirnaty (BioNTech/Pfizer) VE against Covid-19-related

hospitalization was 93% (95% CI 89%–95%) and 85% (95% CI 82%–87%) 14–90 and 91–180 days after the

second dose; VE increased to 95% (95% CI 94%–96%) 14–60 days after the third dose. VE of other

homologous and heterologous three dose series was similar. Protection against severe Covid-19 requiring

ICU treatment was even better. Since January 1, 2022, Comirnaty VE was 98% (95% CI 92%–99%) and 92%

(95% CI 87%–95%) 14–90 and 91–180 days after the second and 98% (95% CI 95%–99%) 14–60 days after

the third dose.

Conclusions.

VE against severe Covid-19 is high among the elderly. It waned slightly after two doses, but a third restored

the protection. VE against severe Covid-19 remained high even after the emergence of Omicron.

Keywords: Covid-19 hospitalization, Covid-19 vaccines, elderly cohort, SARS-CoV-2 omicron variant, waning

vaccine effectiveness

Background

The elderly are highly vulnerable to severe coronavirus disease 2019 (Covid-19) (1) and, therefore, protecting them is essential to reduce the disease burden caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Covid-19 vaccinations prevent SARS-CoV-2 infections and decrease the number of Covid-19 hospitalizations in a population (2–7).

As many other European countries, Finland has mainly used two mRNA Covid-19 vaccines, Comirnaty and Spikevax, and one adenovirus vector Covid-19 vaccine, Vaxzevria (Table 1). In September 2021, Finland started its booster vaccination campaign to improve the protection especially for the elderly (8). The initial recommendation was to adhere to homologous vaccine series, but lately with increasing evidence of good effectiveness (9,10), heterologous series have also been encouraged.

Vaccine effectiveness (VE) generally describes the protective direct effect of vaccination. In the elderly, VE against severe Covid-19 is high after the second dose, but it decreases during the following six months (4,11–14). A third dose increased the VE against infection among adults in multiple observational studies (11,15–18). However, only a few studies have investigated how well the third dose boosts the VE against severe disease among the elderly (17,19,20). Furthermore, VE may decrease because of the recently emerged Omicron variant, which is more capable of evading both natural and vaccine-induced immunity than previous variants (15,16,21–23). Knowledge of VE against severe Covid-19 caused by Omicron is still limited (16,21,23–25) and discussion of the need for further booster doses in the elderly has commenced.

The objective of this study was to estimate the effectiveness of Covid-19 vaccines against severe Covid-19 requiring hospitalization or intensive care unit (ICU) treatment in the elderly in Finland after two and three doses. The effects of time since vaccination, different vaccine series, age and presence of comorbidities on VE were of particular interest. In addition, this study aimed to evaluate the impact of the recently emerged Omicron variant on VE.

Methods

To estimate the effectiveness of Covid-19 vaccines in the elderly population in Finland, we conducted a nationwide, register-based cohort analysis starting on December 27, 2020, and ending on March 31, 2022. The study population was defined as all individuals aged 70 years and over at the beginning of the study and registered in the Population Information System as resident in Finland since January 1, 2020. The unique personal identity code assigned to all permanent residents in Finland allowed linking individual-level data from different sources.

The primary outcome was Covid-19-related hospital admission timely associated with a laboratory-confirmed (by polymerase chain reaction or antigen detection assay) SARS-CoV-2 infection. Using the Care Register for Health Care, which records data on all patients discharged from inpatient care in Finland, we defined Covid-19-related hospitalization as any inpatient encounter with a primary diagnosis of Covid-19 (International Classification of Diseases, 10th revision: U07.1, U07.2), acute respiratory tract infection (J00–J22, J46) or severe complication of lower respiratory tract infections (J80–84, J85.1, J86). A hospitalization was considered timely associated with an infection recorded in the National Infectious Diseases Register if the positive specimen was collected up to 14 days before or seven days after the hospital admission.

The secondary outcome was Covid-19-related ICU admission. ICU admissions were identified from the Finnish Intensive Care Consortium's Quality Register for Intensive Care, which records data on all patients treated in an ICU in Finland. We considered any admission as Covid-19 related if it was marked by the treating physician as due to Covid-19 and if the patient was laboratory-confirmed SARS-CoV-2 positive during the stay.

The exposure was Covid-19 vaccination recorded in the National Vaccination Register, which covers the whole population irrespective of whether they are served by public or private primary health care providers. We distinguished between the three vaccine brands Comirnaty, Spikevax and Vaxzevria and the number of administered doses. The time since vaccination was taken into account by categorizing the time since the last dose using the following cut points: days 21 and 84 after the first dose, days 14, 91 and 181

after the second dose, and days 14 and 61 after the third dose. Thus, a vaccinee's exposure state changed

over time. Being unvaccinated was the reference state.

We considered age, sex, region of residence, residence in a long-term care facility, influenza vaccination in

2019–2020, number of nights hospitalized between 2015 and 2019 and presence of predisposing

comorbidities or medical therapies as confounders. The first three confounders were taken from the

Population Information System. Information on whether a subject was in long-term care at the beginning of

the study or vaccinated against influenza in the last pre-pandemic season were collected from the Care

Register for Social Care and the National Vaccination Register, respectively. We used the data in the Care

Register for Health Care from 2015 onwards to count the number of nights hospitalized between 2015 and

2019 and to assess the presence of comorbidities or medical therapies that predispose to severe Covid-19

according to a recent study of predictors of Covid-19 hospitalization (26). We completed the collection of

data on predisposing comorbidities and medical therapies with primary health care records and

prescription data as outlined in Supplementary Tables 1-2.

Each study subject was considered at risk of the primary and secondary outcomes from the beginning of

the study until the first occurrence of any of the following events: outcome of interest, death, day 14 after

any laboratory-confirmed SARS-CoV-2 infection, vaccination with an unidentified vaccine, a heterologous

second vaccination, vaccination with the third dose prior to the start of the booster campaign

(approximated by September 17, 2021), a fourth vaccination, or end of study. All those events other than

the outcome of interest led to censoring before or at the end of the study.

Using Cox regression with time in the study as the underlying time scale, we compared the hazard of the

two outcomes in vaccinated study subjects with the corresponding hazard in the unvaccinated. The effect

measure of interest was VE, quantified as one minus the hazard ratio adjusted for the seven confounders

categorized as outlined in Table 2. For each VE estimate, we computed either the 95% Wald confidence

interval (CI) or, if there were no cases in one of the two groups, the p-value of the likelihood-ratio test. We

stratified the analysis by age group and presence of comorbidities or medical therapies. Because of the

emergence of Omicron (Supplementary Figure 1), we also estimated VE by calendar time, conducting a

separate regression analysis for each quarter.

To rule out residual confounding, we quantified the association between Covid-19 vaccination and a

potential negative control outcome: inpatient encounters due to injury, poisoning and certain other

consequences of external causes (International Classification of Diseases, 10th revision: S00–T98) recorded

in the Care Register for Health Care. Each study subject was considered at risk of this outcome from the

beginning of the study until the first occurrence of any of the following events: injury, death, vaccination

with an unidentified vaccine or a heterologous two-dose series, vaccination with the third dose prior to

September 17, 2021, or with a fourth dose, or end of study. We compared the hazard of the control

outcome in vaccinated study subjects with the corresponding hazard in the unvaccinated using Cox

regression and expected to find no difference between the groups.

The significance level was set to 5%. The validity of the proportional hazards assumption was examined

visually by plotting the cumulative hazards over time. All analyses were performed in R 4.1.2 (R Foundation

for Statistical Computing, Vienna, Austria). Results concerning the first dose, less common (less than 2000

person-years) vaccine series and the first two weeks after vaccination are presented in the supplementary

data only.

Results

The study cohort included 896 220 individuals aged 70 years and over, and thus 99.8% of the elderly

population in Finland (Supplementary Tables 3-4). At the end of the study, only 5% of those still considered

at risk of Covid-19 hospitalization were unvaccinated; the majority (6% and 65%) were double- or triple-

vaccinated with Comirnaty (Supplementary Table 5, Supplementary Figure 2). The median length of the

dosing interval between the first and second dose and the second and third dose was 84 (interquartile

range, 84–84) and 188 (interquartile range, 181–199) days, respectively. At the end of the study, the triple

vaccinated who were still considered at risk of Covid-19 hospitalization had received their third dose, on

average, 106 (interquartile range, 93–120) days ago. Table 2 shows the distribution of person-years by

vaccination status. The younger and community-dwelling elderly contributed proportionally less vaccinated

person-time than older individuals or those in long-term care. The younger and community-dwelling elderly

had, however, received their first dose later than older individuals and those in long-term care

(Supplementary Table 5).

We observed 2234 Covid-19 hospitalizations and 296 ICU admissions, of which 793 and 159 were among

the unvaccinated (Table 3, Supplementary Figure 3, Supplementary Tables 6-7). In the first 14–90 days since

the second dose of Comirnaty, the VE against hospitalization was 93% (95% CI 89%–95%). In the following

90 days, VE decreased to 85% (95% CI 82%–87%) and subsequently rose to 95% (95% CI 94%–96%) in the

first 14–60 days since the third dose (Figure 1, Supplementary Table 8). The point estimates of VE against

ICU admission were even higher (Figure 1, Supplementary Table 9). The only vaccine series with a

statistically significantly lower VE than the corresponding homologous Comirnaty series was the two-dose

homologous Vaxzevria series whose effectiveness against hospitalization was 74% (95% CI 60%–83%) in the

first 91–180 days.

Increasing age and comorbidities decreased the VE against hospitalization, yet the observed trend of

waning remained unchanged (Supplementary Tables 10-11). In the 14–90 and 91–180 days after the second

dose, the effectiveness of Comirnaty was 95% and 87% in 70-79-year-olds and 87% and 81% in 80-89-year-

olds. In the 91–180 days after the second dose, the presence of either moderately or highly predisposing

comorbidities reduced the VE from 92% to 83% or 82%. In the 14–60 days after the third dose of

Comirnaty, the presence of comorbidities lowered the VE from 98% to 95% or 93%.

The effectiveness of Comirnaty was nearly constant over calendar time (Figure 2, Supplementary Figure 4).

In the fourth quarter of 2021 (Q4), the VE against hospitalization was 90% (95% CI 78%–96%) in the first

14–90 days since the second vaccination and 96% (95% CI 93%–97%) in the first 14–60 days since the third

vaccination (Figure 2, Supplementary Table 12). The corresponding estimates for the first quarter of 2022

(Q1), which was dominated by Omicron, were 91% (95% CI 83%–95%) and 94% (95% CI 92%–95%),

respectively (Figure 2, Supplementary Table 13). However, while in Q4 there was almost no difference in

point estimates in the 14–90 and 91–180 days after the second dose, in Q1 VE seemed to drop to 75% (95%

CI 62%–83%) in the 91-180 days after the second dose (Figure 2). In both quarters, the median times since

the second dose among those vaccinated 14–90 days ago (Q4: 63 days; Q1: 59 days) and 91–180 days ago

(Q4: 146 days; Q1: 130 days) were similar.

The control outcome, i.e., injuries, occurred 36 747 times in the study cohort. Without differentiating

between vaccines, number of doses and time since vaccination, we estimated the hazard ratio at 0.96 (95%

CI 0.93–1.00) and, thus, detected no statistically significant difference between the vaccinated and the

unvaccinated. However, the hazard of injury in those vaccinated with Spikevax was higher than in the

unvaccinated (Supplementary Table 14). The cumulative hazards in vaccinated and unvaccinated individuals

were proportional over time (Supplementary Figure 5).

Discussion

In this study of a nationwide elderly cohort, the Covid-19 vaccines used in Finland were highly effective

against severe Covid-19. After the second and third dose, the VE against Covid-19-related hospitalization

and ICU admission was over 90% for both Comirnaty and Spikevax. However, already during the first 6

months after the second dose, we observed signs of waning VE. Although the confidence intervals

overlapped, VE against hospitalization appeared to decrease faster than VE against ICU admission. A third

dose restored the level of protection to over 90%. Interestingly, the VE was nearly constant during the

study period despite the sporadic emergence of new variants. However, the gradual drop in point estimates

of VE against hospitalization was more evident in the first quarter of 2022, which might be an indicator of

intensified waning after the second dose due to Omicron.

We found no meaningful difference in the effectiveness of the two mRNA vaccines. The effectiveness of

Vaxzevria was, however, slightly lower, although it was still better than the average protection observed

among the elderly after seasonal influenza vaccination (27,28). Nevertheless, individuals who were first

vaccinated with two doses of Vaxzevria and later boosted with mRNA vaccine were as well protected as

those who received three doses of mRNA vaccine.

The present study is concordant with other studies that were conducted prior to the emergence of

Omicron and found limited waning of VE against Covid-19-related hospitalization during the first six months

after the second dose in the elderly (4,7,13,14,29). In England, the VE against hospitalization decreased

from initially excellent 98% to 91% within 5 months from the second vaccination with Comirnaty (4). As in

the present study, Vaxzevria did not offer as high protection as Comirnaty and the VE was generally lower

among individuals with chronic illnesses (4). In line with our findings, VE has also been reported to be

reduced in the elderly aged 80 years and over compared to the younger elderly (14). Due to enhanced

immunosenescence and illness- or treatment-induced immunosuppression, the protection offered by

Covid-19 vaccines may, thus, be weaker among the very fragile elderly, such as residents of long-term

facilities.

Recent studies of adult populations have estimated the VE against severe Covid-19 caused by Omicron at

50–90% after the second dose (16,21,24,25,30) and at approximately 90% after the third dose

(16,21,25,30). Surprisingly, our results from the Omicron-dominated first quarter of 2022 match the upper

limits of these estimates, although our study was restricted to elderly adults, in which VE is expected to be

lower than that in younger adults (4,13,31). High VE against severe Covid-19 caused by Omicron may

partially explain the relatively low hospital burden during the Omicron wave in many European countries

despite skyrocketing infection rates (32). It is difficult to foresee how long the high level of protection will

last. However, this study and another analysis (30) showed that the VE against severe Covid-19 remained at

approximately 90% for at least 2–3 months after the third vaccination. The decision-making regarding the

recommendation of a fourth dose for risk groups, such as the elderly, needs further evidence on the

duration of natural and vaccine-induced immunity as well as VE against severe Covid-19 in various

epidemiological settings.

Finland is one of the few countries that used an extended dosing interval of 12 weeks between the first and

second dose due to shortage of Covid-19 vaccines in the early stage of the vaccination campaign (33). This

interval is considered more immunogenic and might enhance VE against severe disease compared to the

standard dosing interval of 3–4 weeks (7,34,35). Therefore, our results of higher VE might be explained by

the longer dosing interval.

The present study has three major strengths. First, the nationwide cohort was highly representative as it

covered essentially the whole elderly population in Finland. Second, the Finnish setting minimizes the risk

of detection bias. Hospital care in Finland is equally accessible to all permanent residents due to the

national health insurance resulting in low or no costs. Hospitalized patients with Covid-19 symptoms have

been tested at low threshold irrespective of their vaccination status and the testing capacities in hospitals

were at no point exhausted. Therefore, we assume that practically all elderly Covid-19 cases with severe

symptoms requiring hospital care were identified as part of routine clinical practice and were thus eligible

for inclusion in this study. Furthermore, we were able to exclude cases with concomitant asymptomatic or

mild SARS-CoV-2 infection primarily hospitalized for other reasons than Covid-19. Third, we performed a

negative control outcome analysis, which demonstrated that residual confounding after covariate

adjustment would be negligible. Only those vaccinated with Spikevax had a statistically significantly higher

risk of injuries than the unvaccinated indicating the presence of residual confounding due to differential

behavior or frailty.

Although the national registers are known to be comprehensive and have been well maintained before and

during the Covid-19 pandemic, the accuracy of the data has not been validated and information bias cannot

be ruled out. Moreover, we assumed that the study population was randomly mixing so that vaccinated

and unvaccinated subjects were equally exposed to the virus. Unfortunately, we have no data to support

this assumption and differential vaccine uptake in particularly sheltered subpopulations such as residents of

long-term care facilities may have thus led to bias. Although our findings may also apply to other

populations of similar age, they do not necessarily apply to other outcomes. VE against mild disease or

asymptomatic infection is likely lower than VE against severe disease. Another limitation is that the data do

not allow estimation of variant-specific VE. As a surrogate we stratified the analysis by calendar time and

used sequencing data to show which variant dominated each quarter.

Conclusions

Since their introduction at the end of 2020, Covid-19 vaccines have been highly effective in preventing

severe outcomes, such as Covid-19-related hospitalization and ICU admission, in the elderly, who carry the

heaviest disease burden in a population. In our study, we observed signs of waning VE during the first six

months after completion of a two-dose series, but a third dose restored the high level of protection for at

least 2–3 months. Our analysis of data from the first quarter of 2022 suggests that the third dose still

confers high protection against severe Covid-19 even after emergence of Omicron.

Abbreviations

257 VE = Vaccine effectiveness, ICU = Intensive care unit, CI = Confidence interval, Q4 = Fourth calendar

258 quarter, Q1 = First calendar quarter

Declarations

Ethics approval and consent to participate. By Finnish law, the Finnish Institute for Health and Welfare

(THL) is the national expert institution to carry out surveillance on the impact of vaccinations in Finland

(Communicable Diseases Act, https://www.finlex.fi/en/laki/kaannokset/2016/en20161227.pdf). Neither

specific ethical approval of this study nor informed consent from the participants was needed.

Consent for publication. Not applicable.

Availability of data and materials. By Finnish law, the authors are not permitted to share individual-level

register data. The computing code is available upon request.

Competing interests. No financial conflicts related to this study. Finnish Institute for Health and Welfare

(THL) conducts Public-Private Partnership with vaccine manufacturers and has received research funding

from Sanofi Inc., Pfizer Inc., and GlaxoSmithKline Biologicals SA for non-COVID-19-related studies. AAP has

been an investigator in these studies but has received no personal remuneration.

Funding. No external funding, the study was solely conducted by the governmental public health institution

of Finland.

Authors' contributions. UB, EP, TL, TK, HN and AAP participated in the conceptualization of the study. UB

conducted the statistical analysis and EP reviewed the literature. UB and EP drafted the manuscript. UB, EP,

TL, TK, HN and AAP gave comments and revised the manuscript.

Acknowledgments. The authors thank Heini Salo and Toni Lehtonen for the register-based identification of

individuals with medical conditions predisposing to severe Covid-19 as well as Dorothée Obach, Eveline

Otte im Kampe and Kari Auranen for their valuable comments during the conceptualization of the study

(DO, EOiK) and manuscript revision (KA). Additional thanks go to all the colleagues at the Finnish Institute

for Health and Welfare (THL) who curate the register data.

References

1.   Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission,
Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Aug
25;324(8):782.

2.   El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the
mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021 Sep
22;NEJMoa2113017.

3.   Baum U, Poukka E, Palmu AA, Salo H, Lehtonen TO, Leino T. Effectiveness of vaccination against SARS-
CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim
analysis of a nationwide cohort study. Taylor WR, editor. PLoS ONE. 2021 Nov 18;16(11):e0258704.

4.   Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of Protection against
Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med. 2022 Jan 12;NEJMoa2115481.

5.   WHO. WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines [Internet]. [cited 2022 Mar 2].
296   Available from: https://www.who.int/publications-detail-redirect/who-sage-roadmap-for-prioritizing-
297   uses-of-covid-19-vaccines

298   6.   Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the
299   BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021 Sep 15;NEJMoa2110345.

300   7.   Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, et al. Two-Dose Severe Acute
301   Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Effectiveness With Mixed Schedules and
302   Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada.
303   Clinical Infectious Diseases. 2022 Apr 19;ciac290.

304   8.   THL recommends offering a third coronavirus vaccine dose to those over 60 and for medical high-risk
305   groups - Press release - THL [Internet]. Finnish Institute for Health and Welfare (THL), Finland. [cited
306   2021 Dec 16]. Available from: https://thl.fi/en/web/thlfi-en/-/thl-recommends-offering-a-third-
307   coronavirus-vaccine-dose-to-those-over-60-and-for-medical-high-risk-groups

308   9.   Poukka E, Baum U, Palmu AA, Lehtonen TO, Salo H, Nohynek H, et al. Cohort study of Covid-19
309   vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021. Vaccine.
310   2021 Dec;S0264410X21016406.

311   10.   Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA
312   prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort
313   study. The Lancet Regional Health - Europe. 2021 Oct;100249.

314   11.   Berec L, Šmíd M, Přibylová L, Májek O, Pavlík T, Jarkovský J, et al. Real-life protection provided by
315   vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death
316   over time in the Czech Republic: a whole country retrospective view [Internet]. Epidemiology; 2021
317   Dec [cited 2021 Dec 15]. Available from:
318   http://medrxiv.org/lookup/doi/10.1101/2021.12.10.21267590

319   12.   Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning Immunity
320   after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021 Oct 27;NEJMoa2114228.

321   13.   Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of Covid-19 Vaccines over
322   a 9-Month Period in North Carolina. N Engl J Med. 2022 Jan 12;NEJMoa2117128.

323   14.   Machado A, Kislaya I, Rodrigues AP, Sequeira D, Lima J, Cruz C, et al. COVID-19 vaccine effectiveness
324   against laboratory confirmed symptomatic SARS-CoV-2 infection, COVID-19 related hospitalizations
325   and deaths, among individuals aged 65 years or more in Portugal: a cohort study based on data-
326   linkage of national registries February-September 2021 [Internet]. Epidemiology; 2021 Dec [cited
327   2021 Dec 15]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.12.10.21267619

328   15.   Hansen CH, Schelde AB, Moustsen-Helm IR, Emborg HD, Krause TG, Mølbak K, et al. Vaccine
329   effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or
330   booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study [Internet]. Infectious
331   Diseases (except HIV/AIDS); 2021 Dec [cited 2022 Jan 4]. Available from:
332   http://medrxiv.org/lookup/doi/10.1101/2021.12.20.21267966

333   16.   Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Effectiveness of COVID-19
334   vaccines against Omicron or Delta symptomatic infection and severe outcomes [Internet]. Infectious
335   Diseases (except HIV/AIDS); 2022 Jan [cited 2022 Feb 1]. Available from:
336   http://medrxiv.org/lookup/doi/10.1101/2021.12.30.21268565

337   17.   Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, et al. Protection
338   against Covid-19 by BNT162b2 Booster across Age Groups. N Engl J Med. 2021 Dec
339   8;NEJMoa2115926.

340   18.   Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness
341   against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022 Apr 21;386(16):1532–46.

342   19.   Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of
343   the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational
344   study. The Lancet. 2021 Oct;S0140673621022492.

345   20.   Drawz PE, DeSilva M, Bodurtha P, Benitez GV, Murray A, Chamberlain AM, et al. Effectiveness of
346   BNT162b2 and mRNA-1273 Second Doses and Boosters for SARS-CoV-2 infection and SARS-CoV-2
347   Related Hospitalizations: A Statewide Report from the Minnesota Electronic Health Record
348   Consortium. Clinical Infectious Diseases. 2022 Feb 7;ciac110.

349   21.   Thompson MG, Natarajan K, Irving SA, Rowley EA, Griggs EP, Gaglani M, et al. Effectiveness of a Third
350   Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care
351   Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant
352   Predominance — VISION Network, 10 States, August 2021–January 2022. MMWR Morb Mortal Wkly
353   Rep. 2022 Jan 21;71(4):139–45.

354   22.   Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against
355   SARS-CoV-2 Omicron and Delta variants. Nat Med [Internet]. 2022 Feb 21 [cited 2022 Mar 2];
356   Available from: https://www.nature.com/articles/s41591-022-01753-y

357   23.   Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. Risk of severe
358   COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and
359   comorbidities – surveillance results from southern Sweden, July 2021 to January 2022.
360   Eurosurveillance [Internet]. 2022 Mar 3 [cited 2022 Mar 8];27(9). Available from:
361   https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.9.2200121

362   24.   Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine against
363   Omicron Variant in South Africa. N Engl J Med. 2021 Dec 29;NEJMc2119270.

364   25.   Public Health England. COVID-19 vaccine surveillance report - week 8 [Internet]. [cited 2022 Mar 2].
365   Available from:
366   https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/
367   1057599/Vaccine_surveillance_report_-_week-8.pdf

368   26.   Salo H, Lehtonen T, Auranen K, Baum U, Leino T. Predictors of hospitalisation and death due to SARS-
369   CoV-2 infection in Finland: A population-based register study with implications to vaccinations.
370   Vaccine. 2022 May;40(24):3345–55.

371   27.   Baum U, Kulathinal S, Auranen K. Spotlight influenza: Estimation of influenza vaccine effectiveness in
372   elderly people with assessment of residual confounding by negative control outcomes, Finland,
373   2012/13 to 2019/20. Eurosurveillance [Internet]. 2021 Sep 9 [cited 2022 Jan 12];26(36). Available
374   from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.36.2100054

375   28.   Rose A, Kissling E, Emborg HD, Larrauri A, McMenamin J, Pozo F, et al. Interim 2019/20 influenza
376   vaccine effectiveness: six European studies, September 2019 to January 2020. Eurosurveillance
377   [Internet]. 2020 Mar 12 [cited 2022 Mar 2];25(10). Available from:
378   https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000153

379   29.   Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA
380   BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a
381   retrospective cohort study. The Lancet. 2021 Oct;S0140673621021838.

382   30.   Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, et al. Duration of mRNA vaccine
383   protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun. 2022
384   Dec;13(1):3082.

385   31.   Lytras T, Kontopidou F, Lambrou A, Tsiodras S. Comparative effectiveness and durability of COVID-19
386   vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign.
387   Journal of Medical Virology. 2022 Jun 23;jmv.27934.

388   32.   Mathieu E. How do key COVID-19 metrics compare to previous waves? [Internet]. Our World in Data.
389   [cited 2022 Mar 2]. Available from: https://ourworldindata.org/covid-metrics-previous-waves

390   33.   Expert group on vaccines recommends longer gap between coronavirus vaccinations and giving
391   AstraZeneca vaccine to those under 70 - Press release - THL [Internet]. Finnish Institute for Health and
392   Welfare (THL), Finland. [cited 2021 Apr 1]. Available from: https://thl.fi/en/web/thlfi-en/-/expert-
393   group-on-vaccines-recommends-longer-gap-between-coronavirus-vaccinations-and-giving-
394   astrazeneca-vaccine-to-those-under-70

395   34.   Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. Immunogenicity of standard
396   and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021 Nov;184(23):5699-5714.e11.

397   35.   Amirthalingam G, Bernal JL, Andrews NJ, Whitaker H, Gower C, Stowe J, et al. Serological responses
398   and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nat Commun. 2021
399   Dec;12(1):7217.

Tables

402   **Table 1.** Covid-19 vaccines under study

Trade name	International nonproprietary name	Trial name	Manufacturer	Vaccine type	Available in Finland
Comirnaty	Tozinameran	BNT162b2	BioNTech/Pfizer	mRNA vaccine	Since December 27, 2020
Spikevax	Elasomeran	mRNA-1273	Moderna	mRNA vaccine	Since January 20, 2021
Vaxzevria	ChAdOx1-S [recombinant]	AZD1222	Oxford/AstraZeneca	Adenovirus vector vaccine	From February 10 to November 30, 2021

404   **Table 2.** Distribution of person-years in the study of vaccine effectiveness against Covid-19 hospitalization.

	Not vaccinated, person-years (%)	Vaccinated, person-years (%)
Age in years		
70-79	173 830 (24)	535 938 (76)
80-89	57 939 (19)	246 105 (81)
90-115	13 068 (22)	47 634 (78)
Sex		

Male	105 628 (23)	350 917 (77)
Female	139 209 (23)	478 761 (77)
Region of residence		
Helsinki-Uusimaa	56 435 (22)	202 126 (78)
Åland	1145 (19)	4786 (81)
Northern and Eastern Finland	61 478 (23)	205 852 (77)
Southern Finland	59 279 (23)	197 393 (77)
Western Finland	66 501 (23)	219 521 (77)
In long-term care		
No	233 993 (23)	779 369 (77)
Yes	10 844 (18)	50 309 (82)
Influenza vaccination in 2019–2020		
No	133 875 (29)	335 681 (71)
Yes	110 963 (18)	493 997 (82)
Nights hospitalized between 2015 and 2019		
0	132 975 (24)	429 964 (76)
1-5	50 008 (22)	181 812 (78)
6-20	35 615 (22)	126 826 (78)
21+	26 240 (22)	91 077 (78)
Presence of comorbidities or medical therapies[a]		
No predisposing comorbidities	84 412 (24)	261 428 (76)
Only moderately predisposing comorbidities or medical therapies	65 980 (22)	232 391 (78)
At least one highly predisposing comorbidity or medical therapy	94 445 (22)	335 859 (78)
Presence of particular comorbidities or medical therapies[a]		
Severe heart disease	93 843 (22)	337 889 (78)
Type 2 diabetes mellitus	52 035 (22)	182 964 (78)
Immunosuppressive medication	35 443 (22)	127 002 (78)
Actively treated cancer	31 410 (22)	114 354 (78)
Severe chronic respiratory disease	26 198 (22)	93 213 (78)
Neurological condition affecting breathing	22 431 (22)	79 939 (78)
Autoimmune disease	17 062 (22)	60 089 (78)
Type 1 diabetes mellitus or adrenal insufficiency	13 627 (23)	46 922 (77)
Sleep apnea	11 867 (21)	43 736 (79)
Severe kidney disease	5548 (22)	19 162 (78)
Psychotic disease	3833 (29)	9282 (71)
Severe chronic liver disease	1165 (25)	3568 (75)
Organ or stem cell transplantation	560 (22)	1962 (78)
Severe disorder of the immune system	398 (23)	1369 (77)
Down syndrome	3 (19)	13 (81)

405   [a] See study of predictors of Covid-19 hospitalization (26) and Supplementary Tables 1-2.

406 This tabulation uses a binary vaccination status without distinguishing between vaccine brands, number of doses and

407 time since vaccination.

409 **Table 3.** Cases, person-years and cumulative risk (per 100 000) by vaccine, dose and days since last

410 vaccination.

	Covid-19-related hospital admission			Covid-19-related ICU admission		
	Cases	Person-years	Risk[a]	Cases	Person-years	Risk[a]
Not vaccinated	793	244 838	1313	159	244 856	238
Comirnaty + Comirnaty 14-90	33	144 412	108	<5	144 413	8
Comirnaty + Comirnaty 91-180	210	158 116	277	26	158 121	29
Comirnaty + Comirnaty 181+	200	31 354	457	22	31 360	55
Comirnaty + Comirnaty + Comirnaty 14-60	107	69 468	84	9	69 472	3
Comirnaty + Comirnaty + Comirnaty 61+	359	74 262	125	26	74 271	55
Comirnaty + Comirnaty + Spikevax 14-60	28	9222	118	5	9222	13
Comirnaty + Comirnaty + Spikevax 61+	39	5601	325	<5	5602	4
Spikevax + Spikevax 14-90	5	16 589	201	0	16 589	0
Spikevax + Spikevax 91-180	34	17 796	277	<5	17 797	45
Spikevax + Spikevax 181+	23	3315	433	<5	3316	30
Spikevax + Spikevax + Comirnaty 14-60	6	2167	137	0	2167	0
Spikevax + Spikevax + Comirnaty 61+	10	2092	70	0	2092	0
Spikevax + Spikevax + Spikevax 14-60	8	6630	27	0	6630	0
Spikevax + Spikevax + Spikevax 61+	41	5948	109	0	5949	0
Vaxzevria + Vaxzevria 14-90	<5	8248	16	<5	8248	10
Vaxzevria + Vaxzevria 91-180	23	9067	205	5	9067	13
Vaxzevria + Vaxzevria + Comirnaty 14-60	<5	3044	24	0	3044	0
Vaxzevria + Vaxzevria + Comirnaty 61+	12	2434	363	<5	2434	307

411 [a] Estimated based on the Kaplan-Meier estimator.

Figure legends

Figure 1. Vaccine effectiveness against primary outcomes by vaccine, dose and days since last vaccination.

Footnote: Data points: point estimates; lines: 95% confidence interval estimates. All estimates are statistically

significantly different from 0%.

Figure 2. Comirnaty vaccine effectiveness against primary outcomes by quarter, dose and days since last

vaccination.

Footnote: Data points: point estimates; lines: 95% confidence interval estimates. A filled symbol indicates that the

estimate is statistically significantly different from 0%, while an empty symbol indicates that the estimate is not

statistically significantly different from 0%.